Cardiovascular

Featured Article
Gender-Specific Hypertension Guidelines Are Needed to Improve Stroke Prevention
“Further work on the biological mechanisms for sex differences in stroke risk associated with hypertension severity and a need for sex-specific clinical guidelines may be warranted,” the researchers concluded.
Cardiovascular Events More Prevalent in Patients Denied PCSK9 Inhibitor Coverage
“Appropriately identifying and characterizing barriers to PCSK9 inhibitor access, and developing approaches to overcome them, will reduce the clinical and economic burden for patients who are likely…
Walmart Becomes Latest U.S. Retailer to Pull Heartburn Drug Zantac
Walmart became one of the last remaining major US retailers to suspend the sale of over-the-counter heartburn medication containing ranitidine.

Newsfeed

Gender-Specific Hypertension Guidelines Are Needed to Improve Stroke Prevention
Cardiovascular Events More Prevalent in Patients Denied PCSK9 Inhibitor Coverage
Walmart Becomes Latest U.S. Retailer to Pull Heartburn Drug Zantac
CVS Suspends Sales of Zantac Brand and Generic Heartburn Drug During Safety Review
Public Health Program Targeting CVD Risk Proves Cost-Effective
Treating Hypertension Could Decelerate Cognitive Decline
Beware of Intensifying Antihypertensive Regimen at Hospital Discharge
Antiplatelet Agent Recalled
View More

Insights

Ranolazine-Angiotensin Inhibitor Interactions: Reality or Fantasy?
Mark Munger, PharmD, discusses recent study findings, which show that ranolazine increases the adverse effect profile of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, raising concern for patient safety.
How Vitamin D Supplementation, Cardiovascular Disease Risk Relate
Mahmoud Barbarawi, MD, department of internal medicine at the Hurley Medical Center (Flint, Michigan), shares insights from his recent study and highlights gaps of knowledge that still exist between vitamin D supplementation and cardiovascular…
Improving Multiple Outcomes With One Treatment
Kiersten Combs, vice president of US Cardiovascular & Metabolic Disease, and Jim McDermott, vice president of US Medical Affairs and Metabolism, both at AstraZeneca, highlight how the use of Farxiga and other SGLT2 inhibitors impact payers and…
NSAIDs Plus Aspirin Associated With Development of Incident Heart Failure Risk
Mark Munger, PharmD, explains why there is a critical need to develop a treatment to reduce the incidence of NSAID-induced cardiovascular adverse events, especially heart failure.
View More
Back to Top